Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Indacaterol er en én gang dagligt inhaleret β 2-agonist til behandling af kronisk obstruktiv lungesygdom

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Integration af specialiseret palliation og onkologi

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Formodet SARS-CoV-2-dødsfald hos en tidligere rask 50-årig mand

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Akut luftvejsobstruktion grundet uerkendt akalasi efter ukompliceret vaginal fødsel

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Dansk Kvalitetsdatabase for Nyfødte (DKN) -resumé af årsrapport 2018. Indikator 9: antibiotikabehandling

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Lokalanæstesitorakoskopi ved udredning af recidiverende pleuraeffusion

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Characteristics of patients with COVID-19 pneumonia at Hvidovre Hospital, March-April 2020

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Fertility Treatment Resulting in Live Births in Women with Asthma - Associated with Perennial Allergy?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. High suPAR and Low Blood Eosinophil Count are Risk Factors for Hospital Readmission and Mortality in Patients with COPD

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. NORDSTAR - Paving the way for a new era in asthma research

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
The aim of pharmacological treatment of COPD is best possible disease control. Bronchodilators are accepted as the mainstay of COPD therapy. This short review focuses on the available data on indacaterol - a new once-daily beta2-agonist. The analysed studies show that indacaterol has clinically important effects on quality of life, dyspnoea, level of FEV1, hyperinflation, and exacerbation rate in patients with COPD. Indacaterol is therefore in the near future expected to be an important part of maintenance therapy for patients with COPD.
Translated title of the contribution[Indacaterol is a new once-daily beta2-agonist for treatment of COPD]
Original languageDanish
JournalUgeskrift for Laeger
Volume172
Issue number47
Pages (from-to)3260-3
Number of pages4
ISSN0041-5782
Publication statusPublished - 22 Nov 2010

ID: 32722269